Original researchEffects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects
References (32)
- et al.
On the receiving end. V: Patient perceptions of the side effects of chemotherapy in 1993
Ann Oncol
(1996) - et al.
The changeable nature of patient's fears regarding chemotherapy: Implications for palliative care
J Pain Symptom Manage
(2001) - et al.
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy
Lancet
(1991) - et al.
Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis
Eur J Cancer
(2001) - et al.
Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study
Ann Oncol
(1998) - et al.
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
Neuropharmacology
(1996) - et al.
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
Neuropharmacology
(2000) - et al.
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
Eur J Cancer
(2001) - et al.
Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists
Br J Cancer
(1997) - et al.
for the Quality of Life and Sympton Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Effect of postchemotherapy nausea and vomiting on health-related quality of life
Support Care Cancer
(1997)
Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
J Clin Oncol
Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
J Clin Oncol
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis
J Clin Oncol
Management of cisplatin-induced delayed emesis
Oncology
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy
J Clin Oncol
Cited by (87)
Serotonin and 5-HT<inf>3</inf> receptors sensitize human skin cells to direct irradiation cell death but not to soluble radiation-induced bystander signals
2020, Environmental ResearchCitation Excerpt :Promising in vitro agents are often restricted in their ability to translate into viable treatment options due to non-targeted cytotoxic and adverse effects (Mishra and Alsbeih, 2017). Considering this, we used clinically approved 5-HTR antagonist drugs selective for the 5-HT2A (Hedner et al., 1983; Persson et al., 1983; Rashid et al., 2003) and 5-HT3 (Blum et al., 2003; Hope et al., 1996) receptors at physiologically relevant concentrations. Both ketanserin and ondansetron display pro-survival effects in human neonatal foreskin HPV-G cells following low-dose radiation exposure (Fazzari et al., 2012; Poon et al., 2007) but have not been investigated for their ability to modulate IR responses in HaCaT cells.
Stimulation of contractions in pregnant human myometrium is associated with 5-HT3 receptors
2016, International Journal of Obstetric AnesthesiaCitation Excerpt :Our previous study indicated that 5-HT3 receptor antagonists did not alter the contractile pattern of myometrium alone. The present study revealed that granisetron, in a higher concentration than that used therapeutically in humans,27 does not affect myometrial contraction when an exogenous 5-HT3 receptor agonist is present. There are some limitations to our study.
5-HT3 receptor antagonists do not alter spontaneous contraction of pregnant myometrium in vitro
2015, International Journal of Obstetric AnesthesiaCitation Excerpt :Uterine contractility associated with 5-HT3 receptor antagonist was observed at a concentration range comparable to its therapeutic plasma concentration. Pharmacokinetic studies in human volunteers showed that the therapeutic plasma concentrations of ondansetron, granisetron29 and tropisetron30 were 80–100, 17–42 and 10–50 ng/mL, respectively. At such concentrations, the percentage of drug bound to plasma proteins is 73%, 65% and 59–70% for ondansetron, granisetron and tropisetron, respectively.
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
2022, Cancer Chemotherapy and Pharmacology5-HT<inf>2A</inf> and 5-HT<inf>3</inf> receptors contribute to the exacerbation of targeted and non-targeted effects of ionizing radiation-induced cell death in human colon carcinoma cells
2020, International Journal of Radiation BiologyPharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics
2019, Pharmacogenetics and Genomics